MediGene Stock Price, News & Analysis (ETR:MDG1)

€13.11 0.21 (1.63 %)
(As of 01/16/2018 02:56 AM ET)
Previous Close€12.90
Today's Range€12.61 - €13.11
52-Week Range€8.53 - €14.88
Volume136,621 shs
Average Volume168,245 shs
Market Capitalization$292.37 million
P/E Ratio-19.00
Dividend YieldN/A
BetaN/A

About MediGene (ETR:MDG1)

MediGene logoMedigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. It also develops Veregen for the treatment of genital warts; EndoTAG-1 for the treatment of solid tumors; and RhuDex for the treatment of autoimmune diseases. Medigene AG has strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company was founded in 1994 and is headquartered in Planegg, Germany.

Receive MDG1 News and Ratings via Email

Sign-up to receive the latest news and ratings for MDG1 and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolETR:MDG1
CUSIPN/A
Phone+49-89-2000330

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-19
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS(€0.69)
Net IncomeN/A
Net Margins-142.41%
Return on Equity-14.40%
Return on Assets-11.01%

Miscellaneous

EmployeesN/A
Outstanding Shares22,120,000

MediGene (ETR:MDG1) Frequently Asked Questions

What is MediGene's stock symbol?

MediGene trades on the ETR under the ticker symbol "MDG1."

Where is MediGene's stock going? Where will MediGene's stock price be in 2018?

3 analysts have issued 12-month price objectives for MediGene's stock. Their predictions range from €12.00 to €19.00. On average, they anticipate MediGene's share price to reach €14.50 in the next twelve months. View Analyst Ratings for MediGene.

Who are some of MediGene's key competitors?

Who are MediGene's key executives?

MediGene's management team includes the folowing people:

  • Horst Domdey, Chairman of the Supervisory Board (Age 66)
  • Dolores J. Schendel, Chairman of the Executive Management Board, Chief Executive Officer, Chief Scientific Officer
  • Antoinette Hiebeler-Hasner, Deputy Chairman of the Supervisory Board (Age 59)
  • Thomas Taapken, Chief Financial Officer, Member of the Executive Management Board (Age 52)
  • Markus Dangl, Senior Vice President Research & Pre-Clinical Development
  • Kai Pinkernell, Senior Vice President/Chief Medical Officer
  • Olav Zilian, Senior Vice President Corporate Development
  • Yita Lee, Member of the Supervisory Board (Age 46)
  • Keith Manchester, Member of the Supervisory Board (Age 49)
  • Ronald Scott, Member of the Supervisory Board (Age 62)

What is MediGene's stock price today?

One share of MediGene stock can currently be purchased for approximately €13.11.

How big of a company is MediGene?

MediGene has a market capitalization of $292.37 million.

How can I contact MediGene?

MediGene's mailing address is Lochhamer Str. 11, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-2000330.


MarketBeat Community Rating for MediGene (MDG1)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  49 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  86
MarketBeat's community ratings are surveys of what our community members think about MediGene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MediGene (ETR:MDG1) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: €14.50€14.50€14.67€14.67

MediGene (ETR:MDG1) Consensus Price Target History

Price Target History for MediGene (ETR:MDG1)

MediGene (ETR:MDG1) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
12/11/2017Baader BankSet Price TargetBuy€19.00View Rating Details
12/6/2017Independent ResearchSet Price TargetNeutral€12.50View Rating Details
8/8/2017Oddo SecuritiesSet Price TargetBuy€12.00View Rating Details
(Data available from 1/16/2016 forward)

Earnings

Earnings History for MediGene (ETR:MDG1)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

MediGene (ETR:MDG1) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for MediGene (ETR:MDG1)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for MediGene (ETR MDG1)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

MediGene (ETR MDG1) News Headlines

Source:
DateHeadline
Medigene Collaborates with RXi Pharmaceuticals to Further ... - PR Newswire (press release)Medigene Collaborates with RXi Pharmaceuticals to Further ... - PR Newswire (press release)
www.prnewswire.com - December 11 at 6:03 PM
RXI Pharma (RXII) Enters Pact with Medigene to Further Sharpen its Therapeutic T cellsRXI Pharma (RXII) Enters Pact with Medigene to Further Sharpen its Therapeutic T cells
www.streetinsider.com - December 11 at 9:38 AM
MediGene (MDG1) PT Set at €19.00 by Baader BankMediGene (MDG1) PT Set at €19.00 by Baader Bank
www.americanbankingnews.com - December 11 at 6:04 AM
Independent Research Reiterates €12.50 Price Target for MediGene (MDG1)Independent Research Reiterates €12.50 Price Target for MediGene (MDG1)
www.americanbankingnews.com - December 6 at 7:51 PM
MediGene AG (MDG1) PT Set at €12.00 by Independent Research GmbHMediGene AG (MDG1) PT Set at €12.00 by Independent Research GmbH
www.americanbankingnews.com - November 25 at 6:50 PM
MediGene AG (MDG1) PT Set at €13.00 by Independent Research GmbHMediGene AG (MDG1) PT Set at €13.00 by Independent Research GmbH
www.americanbankingnews.com - September 4 at 6:56 AM
Baader Bank Analysts Give MediGene AG (MDG1) a €19.00 Price TargetBaader Bank Analysts Give MediGene AG (MDG1) a €19.00 Price Target
www.americanbankingnews.com - August 3 at 8:56 AM
Medigene AG: Notice to the holders of the zero coupon Convertible Bond 2014/2016 (the "Notes") of Medigene AG (the "Issuer")Medigene AG: Notice to the holders of the zero coupon Convertible Bond 2014/2016 (the "Notes") of Medigene AG (the "Issuer")
finance.yahoo.com - July 13 at 12:52 PM
Medigene joins Max Delbrück Centre and Charité for first clinical TCR study in GermanyMedigene joins Max Delbrück Centre and Charité for first clinical TCR study in Germany
finance.yahoo.com - July 13 at 12:52 PM
Medigene expands TCR platform technology with US patent for method for identification of CD4+ T cell antigensMedigene expands TCR platform technology with US patent for method for identification of CD4+ T cell antigens
finance.yahoo.com - July 13 at 12:52 PM
Medigene participates at five upcoming international conferencesMedigene participates at five upcoming international conferences
finance.yahoo.com - July 13 at 12:52 PM
Medigene reports results of first six months 2016Medigene reports results of first six months 2016
finance.yahoo.com - July 13 at 12:52 PM
Medigene reports outcome of Annual General MeetingMedigene reports outcome of Annual General Meeting
finance.yahoo.com - July 13 at 12:52 PM
Medigene publicizes new bioinformatics tool to predict potential cross-reactivity of cancer and virus antigensMedigene publicizes new bioinformatics tool to predict potential cross-reactivity of cancer and virus antigens
finance.yahoo.com - July 13 at 12:52 PM
Medigene participates at five national and international conferencesMedigene participates at five national and international conferences
finance.yahoo.com - July 13 at 12:52 PM
Medigene participates at six national and international conferencesMedigene participates at six national and international conferences
finance.yahoo.com - July 13 at 12:52 PM
Medigene reports its results for the first nine months of 2016Medigene reports its results for the first nine months of 2016
finance.yahoo.com - July 13 at 12:52 PM
Medigene highlights a new approach for neoantigen-specific TCRs at Neoantigen Summit 2016 in BostonMedigene highlights a new approach for neoantigen-specific TCRs at Neoantigen Summit 2016 in Boston
finance.yahoo.com - July 13 at 12:52 PM
Medigene appoints Dr. Thomas Taapken as Chief Financial OfficerMedigene appoints Dr. Thomas Taapken as Chief Financial Officer
finance.yahoo.com - July 13 at 12:52 PM
Medigene AG to be included in TecDAX IndexMedigene AG to be included in TecDAX Index
finance.yahoo.com - July 13 at 12:52 PM
Medigene participates at four national and international conferences in January 2017Medigene participates at four national and international conferences in January 2017
finance.yahoo.com - July 13 at 12:52 PM
Medigene announces outlicensing of AAVLP technologyMedigene announces outlicensing of AAVLP technology
finance.yahoo.com - July 13 at 12:51 PM

SEC Filings

MediGene (ETR:MDG1) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

MediGene (ETR MDG1) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.